User profiles for Ahmed ME Elreafey
 | Ahmed Mohamed ElrefaeyScientist at The Pirbright Institute Verified email at pirbright.ac.uk Cited by 586 |
Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2
…, N Thakur, TP Peacock, D Bialy, AME Elreafey… - medRxiv, 2021 - medrxiv.org
SARS-CoV-2 variants threaten the effectiveness of tools we have developed to mitigate
against serious COVID-19. This is especially true in clinically vulnerable sections of society …
against serious COVID-19. This is especially true in clinically vulnerable sections of society …
Production of recombinant replication-defective lentiviruses bearing the SARS-CoV or SARS-CoV-2 attachment spike glycoprotein and their application in receptor …
N Thakur, G Gallo, AME Elreafey, D Bailey - Bio-protocol, 2021 - bio-protocol.org
For enveloped viruses, such as SARS-CoV-2, transmission relies on the binding of viral
glycoproteins to cellular receptors. Conventionally, this process is recapitulated in the lab by …
glycoproteins to cellular receptors. Conventionally, this process is recapitulated in the lab by …
[HTML][HTML] A platform technology for generating subunit vaccines against diverse viral pathogens
The COVID-19 pandemic response has shown how vaccine platform technologies can be
used to rapidly and effectively counteract a novel emerging infectious disease. The speed of …
used to rapidly and effectively counteract a novel emerging infectious disease. The speed of …